Dutasteride Capsules

DRUG2 trials

Sponsors

UConn Health, Chong Kun Dang Pharmaceutical

Conditions

Alcohol Use DisorderAndrogenetic Alopecia

Phase 2

Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy

CompletedNCT04098302

UConn HealthAlcohol Use Disorder

Start: 2019-10-15End: 2024-06-28Updated: 2025-05-09

Phase 3

A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

RecruitingNCT06916793

Chong Kun Dang PharmaceuticalAndrogenetic Alopecia

Start: 2025-04-08End: 2028-06-30Target: 288Updated: 2026-09-03